prevention of tardive dyskinesia and brain imagin

Tardive dyskinesia remains a persistent, iatrogenic complication of long-term antipsychotic and dopamine-blocking medication use, making proactive prevention the cornerstone of clinical management. Prioritizing atypical antipsychotics, limiting drug dosage and treatment duration, alongside routine AIMS monitoring and baseline neurological assessment, represent pragmatic, evidence-based strategies to lower TD risk. While adjunctive agents like antioxidants show inconsistent protective benefits, primary prevention still outweighs reactive treatment once involuntary movements become established. Brain imaging adds critical depth to understanding and managing TD. Structural MRI largely serves a diagnostic role, ruling out mimicking neurodegenerative or cerebrovascular conditions, while functional and molecular imaging unveils the underlying neurobiology—striatal dopamine receptor hypersensitivity, disrupted basal ganglia-motor cortex connectivity, and altered dopaminergic transporter function. Though imaging is not yet a routine clinical biomarker for TD prediction, it continues to illuminate disease mechanisms, refine pathophysiological models, and pave the way for future targeted preventive and therapeutic interventions. Overall, optimal TD care combines cautious pharmacological stewardship for prevention with brain imaging as a valuable diagnostic and research tool.